RAVEN BIOTECHNOLOGIES
Raven biotechnologies, Inc., a biotechnology company, focuses on the development of monoclonal antibody therapeutics for treating cancer. Its lead product candidate, RAV12, targets adenocarcinomas and used for the treatment of gastrointestinal, lung, colon, pancreatic, prostate, breast, brain, and ovarian cancer. The company was founded in 1999 and is based in South San Francisco, California. As of July 17, 2008, Raven Biotechnologies, Inc. operates as a subsidiary of MacroGenics, Inc.
RAVEN BIOTECHNOLOGIES
Industry:
Biotechnology Medical Therapeutics
Founded:
1999-01-01
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.macrogenics.com
Total Employee:
51+
Status:
Active
Total Funding:
88.3 M USD
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Amivas
Amivas is an Australian, Canadian and US joint venture that focuses on the development of therapeutics for the treatment of diseases.
Boston Biomedical
Boston Biomedical focuses on the research and development of novel therapeutics to treat cancer.
Planet Biotechnology
Planet Biotechnology is a clinical-stage company that develops monoclonal antibody-based therapeutic and preventative products.
Spark Therapeutics
Spark Therapeutics is focused on the development of gene therapy.
Staten Biotechnology
Staten Biotechnology is a developer of a human monoclonal antibody intended to treat dyslipidemia.
Xori Corporation
XORI Corporation develops technology for discovery and development of monoclonal antibodies which are used to treat cancers, immune
Current Advisors List
Founder
Investors List
Biogen Idec
Biogen Idec investment in Series D - Raven Biotechnologies
Mitsubishi UFJ Capital
Mitsubishi UFJ Capital investment in Series D - Raven Biotechnologies
Hambrecht & Quist Capital Management
Hambrecht & Quist Capital Management investment in Series D - Raven Biotechnologies
CIDC Consultants
CIDC Consultants investment in Series D - Raven Biotechnologies
Milepost Ventures
Milepost Ventures investment in Series D - Raven Biotechnologies
CMEA Capital
CMEA Capital investment in Series D - Raven Biotechnologies
Bear Stearns
Bear Stearns investment in Series D - Raven Biotechnologies
Integra Ventures
Integra Ventures investment in Series D - Raven Biotechnologies
Vulcan Capital
Vulcan Capital investment in Series D - Raven Biotechnologies
U.S. Venture Partners
U.S. Venture Partners investment in Series D - Raven Biotechnologies
Official Site Inspections
http://www.macrogenics.com
- Host name: 77.113.185.35.bc.googleusercontent.com
- IP address: 35.185.113.77
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Raven Biotechnologies"
MacroGenics – Developing innovative antibody-based cancer …
We are a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. Click on the link below for …See details»
About Us - MacroGenics
MacroGenics is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of …See details»
Company Overview - MacroGenics
As a biopharmaceutical company, our team of 240+ dedicated individuals is focused on discovering and developing innovative antibody-based therapeutics for the treatment of …See details»
MacroGenics - Crunchbase Company Profile & Funding
MacroGenics is a biotechnology company developing immunotherapeutics to prevent autoimmune disorders, cancer and infectious diseases. Analysts have valued MacroGenics, Inc. (NASDAQ:MGNX) at US$15.10 after its latest results.See details»
MacroGenics, Inc. - LinkedIn
MacroGenics is a leader in the discovery and development of innovative medicines that utilize our next generation antibody-based technologies. Our team of 300+ dedicated individuals is advancing...See details»
MacroGenics - The Org
MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious …See details»
Investors | MacroGenics, Inc.
Nov 5, 2024 · MacroGenics is a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal antibody-based therapeutics for the …See details»
MacroGenics' Leadership Team - Team members and org chart
The leadership team at MacroGenics has a history of experience in the medical and legal fields, as well as experience in business and finance. The team has members who graduated from …See details»
MacroGenics' CEO and Executive Team - Team members and org …
The executive team at MacroGenics has a history of experience in the medical field as well as business. Many on the team have worked at the FDA, NCI, and various pharmaceutical …See details»
Scott Koenig, M.D., Ph.D. - MacroGenics, Inc.
Dr. Koenig has been our President, Chief Executive Officer and a director since September 2001 and was one of our co-founders. Prior to joining MacroGenics, Dr. Koenig served as Senior …See details»
Our Living Values - MacroGenics
The following list of our living values reflects what is most important to us as an organization and drives all that we do. We are unwavering in our commitment to these values, which represent …See details»
MacroGenics Company Profile - Office Locations, Competitors
Oct 29, 2024 · MacroGenics, Inc. is a biopharmaceutical company focused on discovering and developing antibody-based therapeutics for the treatment of cancer, as well as various …See details»
MacroGenics - Contacts, Employees, Board Members, Advisors
MacroGenics is a biotechnology company developing immunotherapeutics to prevent autoimmune disorders, cancer and infectious diseases.See details»
MacroGenics - Nature Biotechnology
One of MacroGenics' cofounders, Jeffrey Ravetch of the Rockefeller University (New York), was the first to show that the biological outcome of an antigen–antibody reaction in vivo depended …See details»
MacroGenics - Overview, News & Similar companies - ZoomInfo
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics f Read more. Is this data …See details»
MacroGenics, Inc. (MGNX) Stock Price, News, Quote & History
MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States.See details»
Platforms – MacroGenics
MacroGenics has extensive experience applying its proprietary multi-specific DART and TRIDENT platforms to develop molecules that redirect T-cell activation and killing which: (1) recognize …See details»
MGNX Stock Price Quote - Morningstar
6 days ago · Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, …See details»
Nivolumab in Patients With Advanced or Metastatic Malignancies ...
1 day ago · PURPOSETo report on CheckMate 627 (ClinicalTrials.gov identifier: NCT02832167), a phase II adaptive basket design trial of nivolumab in uncommon advanced/metastatic …See details»
Corporate Responsibility 2023 - MacroGenics
We are a biopharmaceutical company with a mission to develop, manufacture and commercialize innovative monoclonal antibody-based, life-changing medicines to transform the lives of …See details»